💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Velpatasvir

CHEMBL3545062 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
883.0 g/mol
LogP
6.2
Phase
4

Velpatasvir is a pan-genotypic NS5A inhibitor that blocks the nonstructural protein 5A of hepatitis C virus (HCV), which is essential for viral RNA replication and virion assembly. It is used in combination with sofosbuvir (Epclusa) or sofosbuvir and voxilaprevir (Vosevi) for the treatment of chronic HCV infection across all six major genotypes. Its pan-genotypic activity simplifies treatment by eliminating the need for genotype testing before initiating therapy.

分子量

883.0000 g/mol

LogP

6.20

TPSA

193.00 Ų

リピンスキーの五則

不適合

治療領域

Cardiovascular Disease Non-Alcoholic Fatty Liver Disease Lymphoma HIV/AIDS Hepatitis C Heart Failure

作用機序

Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C49H54N8O8

                    

                    
                    

                        
HBD / HBA

                        
4 / 10

                    

                    
                    

                        
回転可能結合数

                        
13

                    

                    
                    
                    

                        
重原子数

                        
65

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
Velpatasvir is a pan-genotypic NS5A inhibitor that blocks the nonstructural protein 5A of hepatitis C virus (HCV), which is essential for viral RNA replication and virion assembly. It is used in combination with sofosbuvir (Epclusa) or sofosbuvir and voxilaprevir (Vosevi) for the treatment of chronic HCV infection across all six major genotypes. Its pan-genotypic activity simplifies treatment by eliminating the need for genotype testing before initiating therapy.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits the NS5A protein of hepatitis C virus, disrupting viral RNA replication and virion assembly.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Velpatasvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3545062.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 67683363.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.